Wu Chou Su

Best Publications

• Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

  Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  4403
  Citations

• Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

  Lecia V. Sequist;James Chih-Hsin Yang;Nobuyuki Yamamoto;Kenneth John O'Byrne

  3555
  Citations

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

  Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  3207
  Citations

• AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

  Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  2236
  Citations

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  1331
  Citations

• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

  Vincent A. Miller;Vincent A. Miller;Vera Hirsh;Jacques Cadranel;Yuh Min Chen

  1310
  Citations

• Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1

  Yue E. Chin;Motoo Kitagawa;Wu Chou S. Su;Zhi Hao You

  1009
  Citations

• Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

  James Chih Hsin Yang;Myung Ju Ahn;Dong Wan Kim;Suresh S. Ramalingam

  558
  Citations

• Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

  Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  522
  Citations

• Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial

  James Chih Hsin Yang;Jin Yuan Shih;Wu Chou Su;Te Chun Hsia

  496
  Citations

• Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

  Lecia V. Sequist;Ji Youn Han;Myung Ju Ahn;Byoung Chul Cho

  395
  Citations

• Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.

  Qing Lan;Chao A. Hsiung;Keitaro Matsuo;Yun Chul Hong

  362
  Citations

• Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.

  Wu Chou S. Su;Motoo Kitagawa;Ninrong Xue;Bing Xie

  354
  Citations

• Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

  Yi Long Wu;Li Zhang;Dong Wan Kim;Xiaoqing Liu

  334
  Citations

• Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion

  H. H. Yeh;Wu-Wei Lai;Helen H.W Chen;Hsiao-Sheng Liu

  320
  Citations

• Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non–Small Cell Lung Cancer

  Helen H.W. Chen;Nan Tsing Chiu;Wu Chou Su;How Ran Guo

  312
  Citations

• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.

  Chao Hua Chiu;Cheng Ta Yang;Jin Yuan Shih;Ming Shyan Huang

  257
  Citations

• Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.

  Roy S. Herbst;Edward B. Garon;Dong Wan Kim;Byoung Chul Cho

  256
  Citations

• LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

  James Chih-Hsin Yang;Martin H. Schuler;Nobuyuki Yamamoto;Kenneth John O'Byrne

  242
  Citations

• Targeted Paclitaxel by conjugation to iron oxide and gold nanoparticles.

  Jih Ru Hwu;Yu Sern Lin;Thainashmuthu Josephrajan;Ming-Hua Hsu

  240
  Citations